We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





New COVID-19 ELISA Test Measures Levels of Neutralizing Antibodies Against Six Common SARS-CoV-2 Variants

By LabMedica International staff writers
Posted on 04 May 2021
Print article
Illustration
Illustration
A new ELISA test measures levels of neutralizing antibodies against six common variants of the SARS-CoV-2 virus.

AXIM Biotechnologies, Inc. (San Diego, CA, USA) has developed a new test that measures levels of immune protection against each of the variants of SARS-CoV-2 in parallel fashion. The test takes less than two hours to complete and can provide an indication of relative risk of infection with each variant. SARS-CoV-2 variants from Brazil, South Africa, California and the UK have been shown to be more infectious and potentially more deadly than the original Wuhan strain due to mutations in the viral spike protein. This has caused concern because current COVID-19 vaccines are based on the spike protein in the Wuhan strain and it is not known how well the vaccines protect against the other variants.

The ELISA test is the most widely used type of immunoassay in diagnostic and research labs. ELISA is a high throughput test used to detect or quantify various biomolecules, including antibodies against pathogens or pathogen-derived proteins. ELISA is simple, sensitive, requires only microliter quantities of test samples and can be automated.

“The new test may also provide vaccine companies with valuable information for how well their vaccines protect against SARS-CoV-2 variants,” said John W. Huemoeller II, AXIM Biotech CEO. “If vaccine companies begin to include variants in their vaccine, the new test will be able to measure specific protective antibody responses to the variants. We hope this cutting edge work will be helpful as the more infectious variants begin to predominate worldwide.”

Related Links:
AXIM Biotechnologies, Inc.

New
Gold Supplier
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
COVID-19 Coronavirus and Influenza A/B Virus Real Time PCR Kit
New
Gold Supplier
Integrated Immunoassay & Chemistry System
Dimension EXL with LM
New
COVID-19 Antigen Rapid Test
OnSite COVID-19 Ab Rapid Test
New
Gold Supplier
COVID-19 Nucleic Acid Releaser (For PCR)
Nucleic Acid Releaser (For PCR)

Print article
BIOHIT  Healthcare OY
Mayo Medical Laboratories

Channels

Molecular Diagnostics

view channel
Image: Photograph of the novel capsule-based smell test (Photo courtesy of Queen Mary University of London)

A Novel Capsule-Based Smell Test for Diagnosis of Neurological and Respiratory Diseases

To aid in diagnosing diseases where loss of the sense of smell is a symptom, such as in chronic neurological conditions like Parkinson's and Alzheimer's diseases and in acute respiratory infections such... Read more

Pathology

view channel
Image: The Hamamatsu Photonics Nanozoomer 1 Digital Slide Scanner (Photo courtesy of University of Adelaide)

Genetic Background and Clinicopathologic Features Established for Adult-Onset Nephronophthisis

Nephronophthisis (NPH) is a genetic disorder of the kidneys which mainly affects children. It is classified as a medullary cystic kidney disease. The disorder is inherited in an autosomal recessive fashion... Read more

Industry

view channel
Image: DxA 5000 Fit (Photo courtesy of Beckman Coulter)

Beckman Coulter Becomes First Diagnostics Company to Offer Workflow Automation Specifically for Mid-Volume Laboratories

Beckman Coulter (Brea, CA, USA) has announced the global launch of the DxA 5000 Fit, a workflow-automation solution designed to fit into medium-sized labs that run fewer than 5,000 tests a day.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.